Keywords: higher, ulcer, risk, plavix, study, shows, french
Higher ulcer risk from Plavix, study shows
Article | 31 January 2005
French drugmaker Sanofi-Aventis' flagship product, the antithrombotic blockbuster Plavix (clopidogrel), which is marketed as as a "kinder-on-the-stomach" substitute for aspirin, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
